Ocular Therapeutix, Inc. (OCUL) Stock Price & How to Invest
Last updated November 2026
Short answer
You can invest in Ocular Therapeutix (OCUL) by buying shares or fractional shares at any major broker, through a biotech ETF that holds it, or as one holding in a thematic basket. OCUL is a clinical-and-commercial-stage eye-disease biotech whose story is really a bet on one drug: AXPAXLI, an injectable sustained-release treatment for wet age-related macular degeneration that beat the standard of care in a Phase 3 trial and is headed for a planned FDA filing in the fourth quarter of 2026. The shares closed at ~$5.68 on November 20, 2026, down ~52% year to date after a September drop on competitor data and a further slide following a third-quarter miss. It is a high-risk, catalyst-driven biotech, not an income or value stock.
OCUL stock price
As of 2026-11-20, Ocular Therapeutix, Inc. (OCUL) last closed at $5.57, down 54.5% over the past year. Over the past 52 weeks it has traded between $5.57 and $16.11.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Ocular Therapeutix, Inc.'s investor relations page. Walnut is informational, not investment advice.
OCUL key stats
At $5.57 on November 20, 2026, Ocular Therapeutix, Inc. (OCUL) has a market cap of $1.2B. It next reports earnings around February 4, 2027 (estimated).
- Market cap
- $1.2B
- Price to book
- 2.8
- Beta
- 1.22
- Next earnings
- around February 4, 2027 (estimated)
Market cap, P/E and yield are measured at the $5.57 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Ocular Therapeutix, Inc. (OCUL)?
The last two weeks for Ocular Therapeutix, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- OCUL closed at $5.57 on November 20, 2026, down 10.3% over the past five trading days (from $6.21).
- Ocular Therapeutix, Inc. next reports quarterly results around February 4, 2027 (estimated).
- On November 9, 2026, Ocular Therapeutix, Inc. filed an 8-K with the SEC reporting a change in its directors or officers (Item 5.02). Read the 8-K on sec.gov
- On November 9, 2026, Ocular Therapeutix, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 9, 2026, Ocular Therapeutix, Inc. filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
- On November 17, 2026, HC Wainwright & Co. kept its Buy rating and $28.00 target.
- On November 10, 2026, HC Wainwright & Co. raised its target to $28.00 from $25.00 (Buy).
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Ocular Therapeutix, Inc. (OCUL) latest quarter
Ocular Therapeutix reported revenue of $12.9 million for Q3 2026, down 11% from a year earlier (Ocular Therapeutix, Nov 9, 2026).
Source: Ocular Therapeutix Q3 2026 results, Nov 9, 2026. Full earnings breakdown
What does Ocular Therapeutix, Inc. (OCUL) do?
Ocular Therapeutix is a Massachusetts-based biopharmaceutical company focused on diseases and conditions of the eye, built around its proprietary bioresorbable hydrogel technology that delivers drugs to the eye over an extended period from a single administration. Its only approved, revenue-generating product is DEXTENZA, a dexamethasone insert placed in the tear duct to treat inflammation and pain after eye surgery and, more recently, allergic eye itching. DEXTENZA generates modest sales, about $50 million over the last twelve months and slightly lower than a year ago, so the company is effectively pre-profit and funds itself with a large cash balance while it invests heavily in clinical development.
The investment picture is dominated by AXPAXLI (axitinib intravitreal implant), a hydrogel that slowly releases a tyrosine kinase inhibitor to suppress the abnormal blood-vessel growth behind wet AMD and other retinal diseases. In its Phase 3 SOL-1 trial, AXPAXLI met a superiority endpoint versus the anti-VEGF drug aflibercept (Eylea) with a highly statistically significant result, and about two-thirds of patients were rescue-free at 12 months after one injection, according to the company's third-quarter call. Ocular still plans to submit the FDA filing in the fourth quarter of 2026 under the 505(b)(2) pathway, built on SOL-1 one-year efficacy and safety data from SOL-1 and SOL-R. It moved the SOL-R primary endpoint to week 40, with topline efficacy now expected in the first quarter of 2028, changed SOL-X to test once-yearly dosing, and is enrolling HELIOS-3 in diabetic retinal disease. Cash was about $530.6 million at September 30, 2026 (down from ~$598.6 million at June 30), with a runway guided into 2028 that excludes the full cost of a launch.
The stock has had a rough autumn. In the last week of September 2026 OCUL suffered its worst week in about two and a half years after rivals posted positive long-acting data: Kodiak Sciences' DAYBREAK study met its main goals, with Zenkuda matching Eylea on vision at one year and 54% of Zenkuda patients on a six-month schedule, and 4D Molecular Therapeutics started a late-stage trial of its one-time gene therapy 4D-150. Third-quarter results on November 9 added pressure: revenue of ~$12.9 million fell short of the ~$13.7 million consensus and the loss of $0.42 a share was wider than the expected $0.35. The shares closed at ~$5.68 on November 20, 2026, near the bottom of their 52-week range, down ~12.7% over one month, ~52.0% year to date and ~51.6% over one year, for a market value near ~$1.25 billion.
What's driving Ocular Therapeutix, Inc. (OCUL)?
1. AXPAXLI in wet AMD.
The lead asset is a sustained-release axitinib implant aimed at reducing the frequent anti-VEGF injections wet-AMD patients currently need. In the Phase 3 SOL-1 trial it met a superiority primary endpoint versus aflibercept (p=0.0006), with a larger share of patients maintaining vision. A durability and label advantage over standard care is the central driver of the company's value. Ocular plans to submit AXPAXLI to the FDA in the fourth quarter of 2026 after a positive pre-NDA meeting in September, which puts a possible launch in 2027. Management says it will seek a label with a superiority claim and flexible 6-to-12-month repeat dosing and use it to support premium pricing; none of that is approved yet.
2. Expanding Phase 3 pipeline.
Beyond SOL-1, Ocular is running the SOL-R registrational trial, whose primary endpoint moved to week 40 with topline efficacy expected in the first quarter of 2028, and SOL-X, which now tests a 48-week (once-yearly) maintenance interval. HELIOS-3 is enrolling patients with diabetic retinal disease on once-yearly dosing. Success across multiple retinal indications would broaden AXPAXLI's addressable market well past wet AMD, though each trial adds cost and its own binary risk.
3. Approved product plus hydrogel platform.
DEXTENZA provides real, if modest, commercial revenue (around $52 million in 2025 and ~$50 million over the last twelve months, down ~11.5% year over year in the third quarter) and a fielded sales infrastructure. The underlying bioresorbable hydrogel delivery platform is reusable across drugs and diseases, giving the company a technology base that could support additional products over time.
4. Well-funded balance sheet.
Cash was about $530.6 million at September 30, 2026, down from ~$598.6 million three months earlier and ~$666.7 million at March 31, and management has guided that the balance funds operations, including multiple Phase 3 programs, into 2028. Trailing operating cash outflow ran ~$253 million, so the runway is real but not open-ended, and the guidance excludes the full cost of a commercial launch of AXPAXLI.
5. Competitive bar rising in long-acting wet AMD
In late September 2026 Kodiak Sciences reported that its DAYBREAK study met its main goals, with Zenkuda matching Eylea on vision at one year, 54% of patients on a six-month dosing schedule and a 0.5% cataract rate, and Kodiak plans its own FDA filing in the fourth quarter. 4D Molecular Therapeutics moved its one-time gene therapy 4D-150 into a late-stage trial. OCUL fell about 21% on the first trading day after the news. RBC called the drop overdone, citing AXPAXLI sales potential near $1 billion a few years after launch, but the episode shows how much of the valuation rests on AXPAXLI's position relative to other long-acting options.
What are the risks to Ocular Therapeutix, Inc. (OCUL)?
The stock is a high-risk, single-asset biotech: most of its value depends on AXPAXLI clearing remaining trials, winning FDA approval, and then being adopted by retina specialists who are comfortable with established anti-VEGF drugs. Wet AMD is intensely competitive, with entrenched blockbusters like Regeneron's Eylea and Roche's Vabysmo plus other long-acting and gene-therapy approaches in development. The company is deeply unprofitable, posting net losses of about $88.6 million in the first quarter of 2026, $78.8 million in the second and $94.8 million in the third (~$327 million over the trailing twelve months), and it may need additional capital that could dilute shareholders, especially since its runway guidance excludes the full cost of a launch. Regulatory setbacks, trial delays, safety findings, or slower-than-hoped commercial uptake could each move the shares sharply lower, and DEXTENZA revenue, which fell year over year in the third quarter, is too small to cushion a pipeline disappointment. Competition is now more concrete: Kodiak Sciences' Zenkuda posted positive one-year Phase 3 data in September 2026 with a filing planned for the same quarter as AXPAXLI's, so the two long-acting options could reach the market on similar timelines.
What is the Ocular Therapeutix, Inc. (OCUL) forecast?
11 analysts publish price targets on OCUL, averaging $25.73 as of November 2026, or +361.9% against the $5.57 share price on November 20, 2026. The published targets run from $14.00 to $34.00, a wide spread, and the ratings split 12 buy, 0 hold, 0 sell. Over the last six months there have been 4 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full OCUL forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is OCUL a buy or a sell?
We give no verdict on Ocular Therapeutix, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. AXPAXLI in wet AMD. The lead asset is a sustained-release axitinib implant aimed at reducing the frequent anti-VEGF injections wet-AMD patients currently need. The most optimistic published target, $34.00, assumes this works close to its best case.
The case against. The stock is a high-risk, single-asset biotech: most of its value depends on AXPAXLI clearing remaining trials, winning FDA approval, and then being adopted by retina specialists who are comfortable with established anti-VEGF drugs. The most pessimistic target, $14.00, is roughly what OCUL is worth if this bites instead.
Read the full bull and bear case on OCUL, including what would have to change to break either one. Walnut is not an investment adviser.
Has Ocular Therapeutix, Inc. (OCUL) split its stock?
No. Ocular Therapeutix, Inc. (OCUL) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Ocular Therapeutix, Inc. (OCUL) valued?
Market cap, P/E and dividend yield at today's price are in the OCUL key stats above. The business figures below come from Ocular Therapeutix, Inc.'s reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$50 million
- Revenue (Q3 2026): ~$12.9 million, down ~11.5% year over year, vs ~$13.7 million consensus
- Net loss (TTM): ~-$327 million (~-$1.44 per share)
- Q3 2026 EPS: ~-$0.42 vs ~-$0.35 consensus
- Cash and equivalents (Sept 30, 2026): ~$530.6 million, ~$80 million of debt
As of November 2026: Ocular is effectively a pre-profit biotech: DEXTENZA sales are small and slipped year over year in the third quarter while R&D spending funds several Phase 3 trials, keeping the net loss near $80-95 million a quarter. At ~$1.25 billion the market value sits roughly ~$800 million above net cash, so investors are pricing AXPAXLI's prospects well below the ~$1.8 billion the company was worth in May. The next report is estimated for around February 4, 2027, with consensus near a $0.35 loss per share on ~$13.7 million of revenue, and the 11 analysts Yahoo Finance tracks carry a mean target near $25.7.
Who competes with Ocular Therapeutix, Inc. (OCUL)?
Wet-AMD anti-VEGF leaders
Regeneron (Eylea and high-dose Eylea) and Roche/Genentech (Vabysmo) dominate wet AMD today with widely used anti-VEGF injections. AXPAXLI is designed to compete on dosing durability, so these established, well-reimbursed drugs are the direct comparators any new entrant must displace.
Sustained-delivery and next-generation retina players
Companies pursuing longer-acting or novel retinal therapies, such as EyePoint Pharmaceuticals, Kodiak Sciences and Roche's Susvimo refillable implant, along with gene-therapy developers like 4D Molecular Therapeutics, target the same goal of fewer treatments. They compete with AXPAXLI on the promise of reduced injection burden.
Ophthalmic surgical and specialty biotechs
For DEXTENZA and its broader eye-care platform, Ocular competes with larger ophthalmology franchises like Alcon, Bausch + Lomb, and AbbVie's Allergan eye-care unit, which market post-surgical and dry-eye products and have far greater commercial scale.
What stocks are similar to Ocular Therapeutix, Inc. (OCUL)?
Other names that sit close to OCUL: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Ocular Therapeutix, Inc. (OCUL)
There are three common ways to get OCUL exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so OCUL sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where OCUL fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Ocular Therapeutix, Inc. (OCUL)
Ocular Therapeutix is a small-cap ophthalmology biotech that already sells one approved product (DEXTENZA) but whose valuation rides almost entirely on its lead pipeline drug AXPAXLI reaching FDA approval and commercial adoption in a large, crowded wet-AMD market. It tends to move sharply on trial data and regulatory news, so the odds and timing of AXPAXLI matter far more than current revenue. As of November 20, 2026 the market values the company at about ~$1.25 billion, against ~$531 million of cash at September 30 and ~$80 million of debt.
More on Ocular Therapeutix, Inc. (OCUL)
Whether OCUL is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is OCUL a buy or a sell?, and where the stock could go from here in the OCUL stock forecast.
For income investors, whether OCUL pays a dividend and how the payout looks is covered in does OCUL pay a dividend? And to weigh OCUL against a peer, read the full side-by-side comparisons: OCUL vs AMD and OCUL vs REGN.
Wondering how OCUL fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Ocular Therapeutix, Inc.
Ask Walnut's AI anything about OCUL and see how it fits what you own.
FAQ
What does Ocular Therapeutix do?
+
It is a biopharmaceutical company focused on eye diseases. It sells one approved product, DEXTENZA, for post-surgical eye inflammation and pain, and is developing AXPAXLI, a sustained-release implant for wet age-related macular degeneration and other retinal conditions, using its bioresorbable hydrogel delivery technology.
What is AXPAXLI and why does it matter?
+
AXPAXLI is an injectable hydrogel implant that slowly releases axitinib, a tyrosine kinase inhibitor, to suppress abnormal blood-vessel growth in the retina. It matters because it aims to reduce how often wet-AMD patients need injections, and it beat standard care in the Phase 3 SOL-1 trial, with an FDA filing planned for the fourth quarter of 2026, making it the main driver of the company's value.
Is Ocular Therapeutix profitable?
+
No. It reports large net losses, about $88.6 million in the first quarter of 2026, $78.8 million in the second and $94.8 million in the third (~$327 million over the trailing twelve months), as research and development spending scaled. Its DEXTENZA revenue (around $52 million in 2025 and ~$50 million over the last twelve months) is far too small to cover its clinical-development costs.
How much cash does the company have?
+
Ocular reported about $530.6 million in cash and equivalents as of September 30, 2026, down from ~$598.6 million at June 30 and ~$666.7 million at March 31, against ~$80 million of debt. Management has guided that its cash funds planned operations, including multiple Phase 3 programs, into 2028, though that excludes the full cost of commercializing AXPAXLI. Continued heavy spending, ~$253 million of operating cash outflow over the trailing year, steadily draws it down.
Who are Ocular Therapeutix's main competitors?
+
In wet AMD its key comparators are the established anti-VEGF drugs Eylea from Regeneron and Vabysmo from Roche, plus other sustained-delivery and gene-therapy developers. For its surgical eye products it competes with large ophthalmology franchises like Alcon, Bausch + Lomb, and AbbVie's Allergan. Kodiak Sciences became a more direct long-acting rival in September 2026 when its Zenkuda matched Eylea at one year in the DAYBREAK study.
Why is the market cap so high relative to revenue?
+
At roughly $1.25 billion on November 20, 2026 (down from ~$1.8 billion in May), the market capitalization is about 25 times trailing revenue because investors are valuing the future potential of AXPAXLI in a multi-billion-dollar wet-AMD market rather than current sales. This is typical for a clinical-stage biotech whose lead drug has shown positive Phase 3 data.
What are the biggest risks with OCUL?
+
It is largely a single-asset biotech, so its value hinges on AXPAXLI completing trials, gaining FDA approval, and being adopted despite entrenched competitors. Risks include regulatory setbacks, trial delays, safety findings, potential dilution from raising capital, and a slow commercial ramp, any of which could move the stock sharply.
How can I invest in Ocular Therapeutix?
+
OCUL trades on the Nasdaq, so you can buy shares or fractional shares through any major broker, gain exposure through biotech ETFs that hold it, or include it as one position in a thematic basket. Because it is a volatile catalyst-driven biotech, many investors size it as a small, speculative slice of a diversified portfolio. Walnut is not an investment adviser.
Why did OCUL stock fall in late September 2026?
+
Competitor news. Kodiak Sciences reported that its DAYBREAK Phase 3 study met its main goals, with Zenkuda matching Eylea on vision at one year and many patients on six-month dosing, and 4D Molecular Therapeutics started a late-stage trial of its gene therapy 4D-150. OCUL closed down about 21% on the first day and logged its worst week in roughly two and a half years, even though Ocular reported no setback of its own and still plans an FDA filing for AXPAXLI in the fourth quarter of 2026.
How has OCUL stock performed in 2026?
+
As of the November 20, 2026 close of ~$5.68, OCUL was down ~52.0% year to date, ~51.6% over one year and ~12.7% over the past month, at the bottom of its 52-week range of ~$5.65 to ~$16.44. The 11 analysts Yahoo Finance tracks carry a mean target near $25.7 and a strong-buy consensus. Walnut is not an investment adviser, and analyst targets are opinions, not forecasts this page endorses.
How did Ocular Therapeutix do in its latest quarter?
+
For the third quarter of 2026, reported November 9, revenue was ~$12.9 million, down ~11.5% from a year earlier and below the ~$13.7 million consensus, and the loss was $0.42 a share against an expected $0.35, with a net loss of ~$94.8 million. Cash fell to ~$530.6 million. On the call the company kept its fourth-quarter 2026 FDA filing plan for AXPAXLI, moved the SOL-R primary endpoint to week 40 and said SOL-R topline efficacy is expected in the first quarter of 2028. The shares fell on the results.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Ocular Therapeutix, Inc.'s investor relations page or your broker before making investment decisions.